bryan_johnson
@bryan_johnson
Past bets that played out
These are the clearest thesis calls with observable outcomes, linked back to the original videos.
A post announces the speaker will cohost/broadcast the “Enhanced Games” this Sunday—an Olympics-style event where athlete “enhancement” is allowed using FDA-approved medications under physician supervision, with protocols monitored in an IRB clinical trial (link truncated). No companies or sponsors are named.
A post announces the speaker will cohost/broadcast the “Enhanced Games” this Sunday—an Olympics-style event where athlete “enhancement” is allowed using FDA-approved medications under physician supervision, with protocols monitored in an IRB clinical trial (link truncated). No companies or sponsors are named.
A post announces the speaker will cohost/broadcast the “Enhanced Games” this Sunday—an Olympics-style event where athlete “enhancement” is allowed using FDA-approved medications under physician supervision, with protocols monitored in an IRB clinical trial (link truncated). No companies or sponsors are named.
What this channel is watching now
Recent mentions show where this author is concentrating attention right now.
Latest videos and market context
Recent source posts from this author. Create an account to inspect the complete persisted research trail.
@altryne @enhanced_games So many places. They did a great job being social first and making viewing easy and without ...
The post is generic praise for an unnamed product/service being “social first” and making viewing easy; no specific company, product, catalyst, or financial implication is identified.
I’m cohosting the Enhanced Games this Sunday, first time as a broadcaster. It’s the Olympics with enhancement allowed...
A post announces the speaker will cohost/broadcast the “Enhanced Games” this Sunday—an Olympics-style event where athlete “enhancement” is allowed using FDA-approved medications under physician supervision, with protocols monitored in an IRB clinical trial (link truncated). No companies or sponsors are named.
These numbers are shocking. It's like we got a new frontier AI model but for the body. Lilly's phase 3 results for re...
Post highlights very strong Phase 3 weight-loss results for Eli Lilly’s obesity drug candidate retatrutide (large mean weight loss, large fraction achieving ≥30% loss). If accurate/confirmed, it reinforces Lilly’s leadership in incretin-based obesity therapeutics and can shift expectations for future obesity market share and pricing power.
An immortal legacy will never beat being alive.
The source is a motivational statement (“An immortal legacy will never beat being alive.”) with no market, sector, company, macro, or financial content to translate into an actionable investment thesis.
Proof-backed call history
These are recent thesis calls tied to original source content where available.
A post announces the speaker will cohost/broadcast the “Enhanced Games” this Sunday—an Olympics-style event where athlete “enhancement” is allowed using FDA-approved medications under physician supervision, with protocols monitored in an IRB clinical trial (link truncated). No companies or sponsors are named.
A post announces the speaker will cohost/broadcast the “Enhanced Games” this Sunday—an Olympics-style event where athlete “enhancement” is allowed using FDA-approved medications under physician supervision, with protocols monitored in an IRB clinical trial (link truncated). No companies or sponsors are named.
A post announces the speaker will cohost/broadcast the “Enhanced Games” this Sunday—an Olympics-style event where athlete “enhancement” is allowed using FDA-approved medications under physician supervision, with protocols monitored in an IRB clinical trial (link truncated). No companies or sponsors are named.
Post highlights very strong Phase 3 weight-loss results for Eli Lilly’s obesity drug candidate retatrutide (large mean weight loss, large fraction achieving ≥30% loss). If accurate/confirmed, it reinforces Lilly’s leadership in incretin-based obesity therapeutics and can shift expectations for future obesity market share and pricing power.
Post highlights very strong Phase 3 weight-loss results for Eli Lilly’s obesity drug candidate retatrutide (large mean weight loss, large fraction achieving ≥30% loss). If accurate/confirmed, it reinforces Lilly’s leadership in incretin-based obesity therapeutics and can shift expectations for future obesity market share and pricing power.
Post highlights very strong Phase 3 weight-loss results for Eli Lilly’s obesity drug candidate retatrutide (large mean weight loss, large fraction achieving ≥30% loss). If accurate/confirmed, it reinforces Lilly’s leadership in incretin-based obesity therapeutics and can shift expectations for future obesity market share and pricing power.
About this channel
Channel bio, source link, and public-market context from YouTube.
@bryan_johnson
Most recognized assets
Unlock the full track record
Create an account to inspect the complete author history, trust-weighted rankings, and persisted research across authors, theses, and assets.